Immunservice

Immunservice is a specialized biotech firm built around the therapeutic potential of interleukin-2 (IL-2). Founded as a spin-off from the University of Hamburg, it has a dual business model: supplying high-quality, ready-to-use IL-2 cell culture media and related services to the research community, while concurrently developing a proprietary pipeline of localized IL-2 immunotherapies for human and veterinary use. The company is led by founder and IL-2 pioneer Edith Huland and is backed by seed investor High-Tech Gründerfonds, positioning it as a niche player bridging research tools and clinical development in immunotherapy.

Interleukin-2 (IL-2) biology platform specializing in ready-to-use cell culture media for IL-2-dependent immune cells and localized delivery of IL-2 for immunotherapy (inhalation, instillation, injection).

In research reagents, Immunservice competes with large life science suppliers (e.g., Thermo Fisher, Miltenyi) and specialized cytokine vendors. Therapeutically, it faces competition from both approved IL-2 therapy (Proleukin) and numerous biotech/pharma companies developing 'not-alpha' IL-2 variants designed for better safety. Its key differentiation is deep expertise in localized delivery rather than molecule engineering.